Current Prognoses With Metastatic Renal Cell Carcinoma

Santosh Rao, MD, discusses ongoing and potential future research efforts aiming to maximize the benefits that patients with kidney cancer may derive from integrative oncology treatment techniques.

Santosh Rao, MD, discusses the formation of new guidelines informing the use of integrative oncology for patients with kidney cancer from the Society for Integrative Oncology.

The addition of cabozantinib to nivolumab and ipilimumab also appears to improve responses in patients with advanced renal cell carcinoma in the phase 3 COSMIC-313 trial.

In an OncView™ program, David H. Aggen, MD, PhD, Robert S. Alter, MD, Arnab Basu, MD, MPH, FACP, Mehmet Asim Bilen, MD, and Chung-Han Lee, MD, MPH, offer their expert insights for the treatment of RCC.

A panel of experts discuss the updated results of the phase 3 CLEAR trial presented at the 2022 International Kidney Cancer Symposium.

Data from the phase 3 ZIRCON trial evaluating 89Zr-DFO-girentuximab in patients with renal tumors may be practice changing, according to an expert from the University of California Los Angeles.